Primary Biliary Cirrhosis Drugs Market Highlights The Competitive Scenario With Impact Of Drivers
Primary biliary cirrhosis, known as primary biliary cholangitis is a chronic liver disease, which causes liver inflammation, fibrosis, and obstruction in the bile duct leading to destruction of small bile ducts within liver. Cause for primary biliary cirrhosis can be autoimmunity, infection and/or genetic predisposition. Symptoms of primary biliary cirrhosis includes itching, osteoporosis, elevated serum cholesterol, and malabsorption of fat and fat soluble vitamins, which can advance to hepatomegaly, hyperpigmentation, splenomegaly, jaundice, sicca syndrome or Kayser-Fleischer rings. Primary biliary cirrhosis develops over time and may cause the liver to stop working completely in later stages. Most people are diagnosed early, before the disease progresses. Delay in treatment of cirrhosis can cause liver failure and a liver transplant is necessary for survival. Diagnostic tests for primary biliary cirrhosis includes examination of elevated levels of IgM immunoglobulin levels, lipids, cholesterol and bilirubin, liver biopsy, ultrasonography, CT scanning or MRI. Increasing research and development activities and rising incidence of primary biliary cirrhosis is expected to be a major driver for growth of the primary biliary cirrhosis drugs market.
Get The Holistic SAMPLE With Research Methodology: https://www.coherentmarketinsights.com/insight/request-sample/1539
Primary Biliary Cirrhosis Drugs Market – Driver
Currently, only two FDA approved drugs, Ursodeoxycholic acid and Ocaliva, are available in market to reduce cirrhosis progression. However, large number of drugs are in clinical trials and this is expected to propel growth of the primary biliary cirrhosis drug market in the near future. For instance, in 2017, NGM Biopharmaceuticals, Inc. completed phase II clinical trials for its candidate drug NGM 282, an engineered variant of human hormone FGF19, to eliminate bile acid toxicity in primary biliary cirrhosis patients. NGM282 has a unique opportunity to leverage the dual targets of FGF19 without the potential non-tumorigenic property.
Click To Continue Reading On Primary Biliary Cirrhosis Drugs Market
You may be interested
Hydrogen Vehicle Market Positive long-term growth outlook 2018-2025Sayali Tribhuvan - June 24, 2018
Hydrogen Vehicle Market Report provides an analytical assessment of the prime challenges faced by this Market currently and in the coming years, which helps Market participants in…
Hashgraph Market New Research Highlights the Current Trends, Opportunities And Challenges For IndustrySayali Tribhuvan - June 23, 2018
Hashgraph Market Report provides an analytical assessment of the prime challenges faced by this industry currently and in the coming years, which helps market participants in understanding…
Speech Analytics Market Segmentation by Revenue, Present & Future Scenario To 2025Sayali Tribhuvan - June 23, 2018
Speech Analytics Market Report provides an analytical assessment of the prime challenges faced by this industry currently and in the coming years, which helps market participants in…